View Future GrowthCann Group 과거 순이익 실적과거 기준 점검 3/6Cann Group은 연평균 1.2%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.8% 증가했습니다. 매출은 연평균 11.8%의 비율로 증가했습니다. Cann Group의 자기자본이익률은 43%이고 순이익률은 130.3%입니다.핵심 정보1.18%순이익 성장률14.25%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률11.76%자기자본이익률42.97%순이익률130.29%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.공시 • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).모든 업데이트 보기Recent updates공시 • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing공시 • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia공시 • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.공시 • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listing공시 • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering공시 • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering공시 • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.공시 • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024공시 • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m).공시 • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.공시 • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.공시 • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listing공시 • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m).공시 • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offering공시 • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.공시 • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.공시 • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year.Is New 90 Day High Low • Feb 10New 90-day high: €0.52The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: €0.30The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 12New 90-day low: €0.23The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.매출 및 비용 세부 내역Cann Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:CVJ 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 25111512130 Sep 2512-413130 Jun 2513-2213131 Mar 2514-3514131 Dec 2416-4814030 Sep 2417-4916130 Jun 2418-5119131 Mar 2420-4020131 Dec 2321-2920230 Sep 2321-3220330 Jun 2321-3419431 Mar 2318-3523431 Dec 2214-3727530 Sep 2213-3227430 Jun 2211-2628331 Mar 2210-2527231 Dec 219-2426230 Sep 219-2525230 Jun 219-2523231 Mar 217-2219231 Dec 206-1815230 Sep 204-1714230 Jun 202-1714131 Mar 202-1615131 Dec 193-1416130 Sep 193-1315130 Jun 193-1113131 Mar 192-1011131 Dec 181-89130 Sep 181-67130 Jun 181-56131 Mar 180-44131 Dec 170-32030 Sep 170-32130 Jun 170-32130 Jun 160-11030 Jun 150-440양질의 수익: CVJ의 비현금 수익 수준이 높습니다.이익 마진 증가: CVJ는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CVJ는 지난 5년 동안 흑자전환하며 연평균 1.2%의 수익 성장을 기록했습니다.성장 가속화: CVJ는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: CVJ는 지난해 흑자전환하여 지난 해 수익 성장률을 Pharmaceuticals 업계(15.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CVJ의 자본 수익률(43%)은 뛰어남으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 15:16종가2026/06/17 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cann Group Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Cameron BellCanaccord GenuityPaul JenszPAC Partners Securities Pty. Ltd.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
공시 • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024
Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).
공시 • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing
공시 • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia
공시 • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.
공시 • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listing
공시 • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
공시 • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
공시 • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
공시 • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024
공시 • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.
Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m).
공시 • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.
공시 • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.
공시 • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listing
공시 • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m).
공시 • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offering
공시 • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.
Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
공시 • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.
공시 • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year.
Is New 90 Day High Low • Feb 10New 90-day high: €0.52The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: €0.30The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 12New 90-day low: €0.23The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.